ACTRN12617001146381尚未招募不适用
se of Vancomycin in Primary Sclerosing Cholangitis (PSC)-Ulcerative Colitis (UC) and use of Biologics in moderate to severe UC: Comparison of clinical parameters, mucosal healing, biomarkers, faecal microbiome and genotype between responders and non-responders.
Associate Professor Peter Lewindon0 个研究点目标入组 100 人开始时间: 2017年8月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 6 Years 至 18 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating EffectsPrimary Sclerosing CholangitisNCT01802073Stanford University34
终止
2 期
Vancomycin for Primary Sclerosing CholangitisPrimary Sclerosing CholangitisNCT03710122Elizabeth Carey102
招募中
不适用
Primary sclerosing cholangitis under aspects of translational neurology, mental health, and systemic inflammation.Primary sclerosing cholangitistK83.00K83.1Obstruction of bile ductDRKS00025588niversitätsklinikum Essen120
撤回
不适用
Vancomycin Treatment in Recurrent PSC in Liver Transplant PatientsPost- Orthotopic Liver TransplantationPrimary Sclerosing CholangitisNCT03046901Ochsner Health System
进行中（未招募）
1 期
Pyridoxine in primary sclerosing cholangitisPrimary sclerosing cholangitisMedDRA version: 20.1Level: LLTClassification code: 10039717Term: Sclerosing cholangitis Class: 10019805CTIS2023-505155-47-00Oslo University Hospital HF26